Apoptosis pathway via mitochondrial superoxide induction

This cell death pathway is characterized by the induction of apoptosis through excessive production of mitochondrial superoxide anions. This ROS accumulation leads to mitochondrial damage, release of cytochrome c, and activation of the intrinsic apoptotic cascade via pro-apoptotic Bcl-2 family members (Bax, Bak) and caspase enzymes (particularly caspase-9 and caspase-3). In some contexts, this process can lead to caspase-independent cell death, especially when ATP is depleted. The pathway is implicated in diverse pathological and therapeutic settings, including cancer, neurodegeneration, and tissue injury, and can be modulated by drugs that either increase or scavenge mitochondrial ROS. Note: For drug discovery, mitochondrial superoxide induction as a therapeutic approach is mechanistically relevant but not itself a defined molecular target. Instead, researchers often target the individual proteins involved (e.g., Bcl-2, Bax, caspases), ROS-producing enzymes, or the mitochondria directly.

Other names

Mitochondrial superoxide-induced apoptosisROS-mediated mitochondria-dependent apoptosis

Drugs may act by increasing mitochondrial superoxide (pro-apoptotic effect). Antioxidant action (inhibition of ROS to prevent apoptosis). Modulation of Bcl-2 family proteins (shift between pro- and anti-apoptotic balance). Inducing cytochrome c release and caspase activation (intrinsic apoptosis).